Please login to the form below

Not currently logged in
Email:
Password:

Indian patent office

This page shows the latest Indian patent office news and features for those working in and with pharma, biotech and healthcare.

India denies Vertex patent on cystic fibrosis drug Orkambi

India denies Vertex patent on cystic fibrosis drug Orkambi

The Indian Patent Office has refused a patent to Vertex Pharma for its cystic fibrosis therapy Orkambi, saying the drug is not novel. ... India's Kolkata Patent Office declined to approve the Indian version of this patent - first filed in 2008 - on the

Latest news

  • India denies patent on Pfizer's Xeljanz India denies patent on Pfizer's Xeljanz

    The Indian Patent Office rejected Pfizer's patent application for the second time, saying it does not consider the drug to be an invention as it isn't therapeutically more effective ... The IPAB ordered the patent to be reconsidered by another assistant

  • BMS says it defends Sprycel patent in India BMS says it defends Sprycel patent in India

    The latest application - by Mumbai-based speciality drugmaker BDR Pharmaceuticals - has been rejected by the Indian Patent office, according to press reports which cite an affidavit filed by BMS in the ... BDR had been trying to secure a compulsory

  • India could hit Roche and BMS with compulsory licences India could hit Roche and BMS with compulsory licences

    Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration. ... It is described by the Indian patent office as an "involuntary contract between a willing buyer and an unwilling seller imposed and enforced by the State".

  • Thai generic drug programme argument heats up

    PMLive has already reported on a similar case in India, where Novartis is challenging Indian patent law following the domestic patent office's decision to decline protection for its cancer treatment ... However, Indian generic firms, who wish to expand

  • Patent battles in India focus attention on domestic industry expansion

    Swiss-based pharmaceutical company, Novartis, is challenging Indian patent law following the domestic patent office's decision to decline a patent for cancer treatment Glivec. ... Swiss-based pharmaceutical company, Novartis, is challenging Indian patent

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Intellectual property threats in the BRIC markets Intellectual property threats in the BRIC markets

    The recent upholding of the Indian patent office's rejection of Novartis' Glivec patent application is the latest in a series of actions including the compulsory licence of Nexavar and initiation ... However, China also passed the “Measures for the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Spirit, an OPEN Health Company

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....